Pharmacovigilance and Drug Safety Software Market Size & Share 2023 to 2032
Market Size by Functionality (Adverse Event Reporting Software, Issue Tracking Software), Mode of Delivery (On-premise, On-demand), End Use, Global Forecast.
Report ID: GMI6282
|
Published Date: July 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Pharmacovigilance & Drug Safety Software Market Size
Pharmacovigilance and Drug Safety Software Market size was valued at USD 171.7 million in 2022 and is estimated to grow at a CAGR of 6.6% to reach USD 319.9 million by 2032 attributed to the rising number of adverse drug reactions (ADRs) that has increased the need for reliable and efficient pharmacovigilance and drug safety software use.
Pharmacovigilance and Drug Safety Software Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Stringent guidelines by government and regulatory bodies have increased the adoption of pharmacovigilance and drug safety software for drug safety monitoring, signal detection, and risk management. Also, increasing number of drug development and clinical trials has further soared the demand for pharmacovigilance and drug safety software by pharmaceutical companies to effectively monitor the safety profiles of drugs in development and during clinical trials. Further, the adoption of artificial intelligence and machine learning in pharmacovigilance software has proven instrumental in streamlining the process of identifying potential safety issues and improving patient outcomes.
Pharmacovigilance and drug safety software are tools used by pharmaceutical companies, regulatory agencies, and healthcare organizations to monitor, track, and manage the safety and effectiveness of drugs and other medical products. These software systems play a crucial role in the process of pharmacovigilance, which involves the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
COVID-19 Impact
The rapid drug development propelled by the COVID-19 pandemic led to newer drugs, treatments, and vaccines being introduced at a rapid pace in the market. With the increase in the rate of drug development, the role of pharmacovigilance and drug safety software has emerged in managing large quantities of data to assess the risks and benefits of a particular drug. Additionally, the pandemic also highlighted the importance of real-time monitoring, adverse event reporting, and signal detection to identify any potential safety issues associated with new drugs.
Pharmacovigilance & Drug Safety Software Industry Trends
One of the key drivers of the pharmacovigilance and drug safety software market is the rising number of adverse drug reactions (ADR’s) globally. For instance, according to the Agency for Healthcare Research and Quality, in 2018, 3-7% of all hospitalizations in the U.S. were caused due to adverse drug reactions (ADRs). ADRs can have serious implications for patient health and safety, leading to potential legal and financial consequences for pharmaceutical companies. Hence, regulatory authorities are responding to this concern by implementing stricter regulations for drug safety.
Pharmacovigilance and Drug Safety Software Market Restraint
The high cost of ownership, installation, and maintenance of pharmacovigilance and drug safety software are the major challenges that may hamper the industry development by 2032. Many small and medium scale pharmaceutical manufacturers often operate with limited financial resources and may find it difficult to invest in expensive software solutions or to afford regular maintenance fees. Further, the initial costs of acquiring pharmacovigilance software licenses, implementation, and customization can be significant, making it a financial burden for small manufacturers while adopting such software systems.
Pharmacovigilance & Drug Safety Software Market Analysis
By functionality, the pharmacovigilance and drug safety software market is classified into adverse event reporting software, drug safety audits software, issue tracking software, fully integrated software, and other functionalities. The fully integrated software segment held 32.9% industry share in 2022. attributed to the increasing demand for automated, user-friendly, and technologically advanced platforms that enhance operational efficiency and ensure adherence to stringent safety regulations. Also, fully integrated software ensures data integrity and consistency, enabling efficient data retrieval, analysis, and reporting. Such aforementioned factors have increased the adoption of fully integrated software.
Based on mode of delivery, the pharmacovigilance and drug safety software market is segmented into on-premise and on-demand/cloud-based (SaaS). The on-demand/cloud-based (SaaS) segment held a significant share of the market of 56.7% in 2022. High adoption of on-demand/cloud-based (SaaS) software can be attributed to several advantages such as enhanced accessibility, seamless scalability, and reduced infrastructure costs. The on-demand model also facilitates real-time collaboration among stakeholders, enabling faster decision-making and comprehensive data analysis. Also, the SaaS model's flexibility and ease of implementation have allowed companies to access advanced pharmacovigilance tools that were once exclusive to larger enterprises.
By end-use, the pharmacovigilance and drug safety software market is divided into pharmaceutical & biotechnology companies, contract research organizations (CROS), business process outsourcing (BPO) firms, and other end-users. The pharmaceutical and biotechnology companies segment accounted for USD 59.5 million in 2022. These companies widely adopt pharmacovigilance and drug safety software solutions to streamline clinical trial programs and to focus on post-market surveillance. By implementing such software, pharmaceutical and biotechnology companies can streamline their pharmacovigilance processes, improve data collection & analysis, and ensure compliance with regulatory requirements.
Moreover, the software helps these companies in reporting adverse events to regulatory authorities, facilitating transparent communication and accountability. Such vast benefits of using this software have increased their adoption by pharmaceutical & biotechnology companies.
North America pharmacovigilance and drug safety software market is accounting for 37.4% of the total market’s revenue in 2022. The increasing demand for efficient and reliable drug safety solutions, coupled with stringent regulatory requirements, has propelled the business gains in the region. Also, the rising prevalence of chronic diseases, the growing number of clinical trials, and the escalating volume of drug approvals have further fueled the demand for pharmacovigilance and drug safety software. High number of CRO’s offering pharmacovigilance outsourcing services in the region is expected to increase the demand for such software.
Pharmacovigilance & Drug Safety Software Market Share
Major market players operating in the pharmacovigilance and drug safety software market include :
Pharmacovigilance & Drug Safety Software Industry News:
The pharmacovigilance and drug safety software market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Functionality
By Mode of Delivery
By End-use
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →